In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX + SASP) seemed superior to MTX alone in the treatment of rheumatoid arthritis (RA). To assess the impact of these therapies on the cytokine cascade, the in iritro production and circulating concentrations of several cytokines and endogenous cytokine antagonists were measured in 30 healthy controls and longitudinally in a subset of 26 patients enrolled in this study. Compared to controls, RA patients had significantly higher circulating concentrations of interleukin-6 (IL-6), soluble receptors for tumour necrosis factor (sTNFR), soluble receptors for interleukin-2 (sIL-2R) and interleukin-1 receptor antagonists (IL-1RA), and their peripheral blood mononuclear cells (PBMNC) showed a higher spontaneous production of interleukin-1/? (IL-1 []), tumour necrosis factor a (TNFa) and IL-1RA (both secreted and cell-associated) and a higher stimulated production of cell-associated TNFa, IL-1RA and (to a lesser extent) IL-1/?. Treatment with MTX alone {n -12) or combined with SASP (n = 14), resulted in significant reductions of circulating IL-6 and sIL-2R but did not alter IL-1 /?, TNFa or IL-1RA concentrations. Decreases in circulating levels of sTNFR and in the in vitro production of cell-associated IL-l/J and IL-1RA after stimulation were only observed in patients treated with MTX + SASP. The concentrations of IL-1RA and sTNFR in the circulation exceeded moderately those of IL-1 /J and TNFa but this is probably insufficient to block IL-1 and TNFa activity. In conclusion, therapy with MTX alone or with SASP modulates IL-6 and sIL-2R concentrations in RA. Decreased production of IL-1/3 and IL-1RA and circulating sTNFR levels were only observed during therapy with MTX + SASP. Whether this relates to the better clinical effect observed with the combination therapy remains to be investigated. Circulating levels of IL-6, sIL-2R and sTNFR seem useful markers of disease activity in RA. K e y w o r d s : Cytokines, Methotrexate, Sulphasalazine, Combination therapy.
T h e involvement of cytokine netw orks in the pathogen esis of rheumatoid arthritis (R A ) is proved beyond discussion [1,2]. Proinflammatory cytokines such as interleukin-1 (IL-1) and tum our necrosis factor a (TNFa) [3, 4] [8, 9] . IL-6, the major inducer o f acute-phase response [10] , Submitted 21 December 1994 ; revised version accepted 27 April 1995.
are present in the rheumatoid synovial membrane and implicated in cell proliferation, syn thesis o f prostaglandins, m etalloproteinases and inter leukin-6 (IL-6) [5], proteoglycan breakdown and bone resorption [1]. Intra-articular injection o f IL-1 [6] and T N F [7] result in joint inflammation and blocking IL-1 and T N F ameliorates several animal m odels o f arthritis

is also present in R A synovial tissue [2] and may amplify the inflammatory process by its action on B-and T-cells [1]. However, in contrast to IL-1 and TNF, IL-6 does not enhance prostaglandins or collagenase production and m ay counteract inflammation by enhancing the synthesis o f tissue inhibitor o f m etalloproteinase-1 [11] and reducing IL-1 and T N F pro-
Correspondence to: P. Barrera [12] . The role of these cytokines in human arthritis is supported by preliminary studies showing improvement during IL-1 [13] , T N F [14] , and IL-6 [15] blockade in RA patients.
The activity of cytokines in biological fluids is subject to modulation by natural inhibitors and soluble cytokine receptors. The IL-1 receptor antagonist (IL-1RA), a competitive inhibitor o f IL-1 which binds to the IL-1 receptors without inducing a biological response [16] is present in the rheumatoid synovial membrane [17] . High concentrations of soluble recep tors for IL-2 (sIL-2R) [18] [19] [20] and TNI [19, 21] have been detected in plasma and synovial fluid of RA patients. The sIL-2R, a soluble form o f the a chain IL-2 receptor, is a marker of lymphocyte activation in vivo [2 2 ] and may be useful to monitor disease activity in RA [18] . The two types of sTNFR (p55 and p75) are shed from the cellular membrane and bind to T N F in solution acting as endogenous T N F antagonists [23] .
Methotrexate (MTX) and sulphasalazine (SASP) are currently used anti-rheumatic drugs. Although their mechanism of action remains unclear, several reports suggest that these drugs may differ in their efleets on circulating cytokines and cytokine production. In vitro studies with MTX have shown inhibitory effects on 747 IL-1 [24] and IL-6 but not T N F bioactivity [25] while SASP has been reported to decrease IL-1 [26, 27] and T N F [27] production and to inhibit the binding of T N F a to its receptor [28] . Furthermore in RA patients, decreases in synovial levels of IL-1 /? [29] , in the pro duction o f IL-1 by peripheral blood mononuclear cells (PBM N C ) [30, 31] and in circulating concentrations of IL-6, p55 sTNFR [19] and sIL-2R [19, 20] have been reported during MTX, whereas treatment with SASP has been associated with reductions in IL-la, IL-1/? and T N F a [32] , but not in sIL-2R [33] or IL-6 [32] concen trations, though the latter was not corroborated in study [34] . To date o f combination therapy with M TX and SASP on cytokines has not been assessed.
'e, after a recent study in our centre showed that the combination of M TX and SASP was superior to M TX alone in the treatment of active RA [35] , we analysed the effects of these therapies on circulating And on the in vitro production of several cytokines and their endogenous antagonists.
PATIENTS
Twenty-six patients with active RA enrolled in a 24-week, randomized, open trial of MTX vs MTX in combination with SASP [35] and 30 healthy controls (laboratory staff) were studied. Cytokine concen trations were assessed at baseline and after 4, 8 and 24
Cytokine production by PBM N C.
The production of IL-1/?, TNFa and IL-1RA was
sT N FR production was not measured since PBM NC do not seem to release these receptors either spontaneously or after LPS stimulation [31] . PBM NC were isolated from heparinized blood by Percoll (Pharmacia, Upsala, Sweden) centrifugation (S 1.075g/ml) at 4°C and washed twice in saline. PBM NC were suspended at a concentration of 5 x 106 cells/ml in RPMI complete medium [RPMI 1640 medium with 20 niM HEPES (Flow, UK) supplemented with 2mM L-glutamine (Gibco, New York, USA), 1 niM pyruvic acid (Sigma, St Louis, MO, USA), 50 /ig/ml gentamicin and 5% heat-inactivated pooled human serum]. Aliquots of 100 ¿¿1 (5 x 10s cells) were *■ Jk * added to 96-well round-bottomed microtitre plates (Greiner, Feirickenhausen, Germany). An equal vol ume of RPMI complete medium with or without lipopolisaccharide (LPS) (50 ng/ml final concentration) was added. The plates were incubated at 37"C in a humidified, 5% C 0 2 atmosphere for 24 h. Thereafter, the supernatants containing secreted cytokines, were centrifuged for 5 min at 13 000#. The remaining cell fractions were resuspended in 200 ¿¿1 RPMI complete medium/well and exposed to three freeze-thaw cycles to lyse the cells and obtain material to measure cellassociated cytokines. The samples were stored at 80°C. The RPM I culture medium, Percoll and saline used in this study were sterile and pyrogen-free. [35] were excluded from cytokine measurements since they were controlled in another centre. Active RA was defined as a disease activity (DA S) > 3 . The DAS is a validated score composed of the Ritchie Articular Index, number of erythrocyte sedimentation rate (ESR) and patient well-being on a visual analogue scale [36] . Twelve patients were allocated to therapy with MTX alone (7.5 mg weekly in a single dose) and 14 patients ition MTX + SASP (2000 mg daily in two doses). If no clinical improvement was observed after 1 the MTX was increas to 15 mg weekly. Non-steroidal anti-inflammatory drugs (N SA ID s) were kept at a stable dose and no corticoat or during the study. distribution-free test for curve analysis [40] . Spear man's rank correlation coefficient was used to elevate correlations between variables at study entry, and between changes in variables after 24 weeks. A twosided P value of 0.05 was considered to be significant. The clinical trial was an open study [35] , but cytokine measurements were performed in a modified single blind fashion.
weeks. Fourteen additional patients enrolled in the original clinical study
M ETHODS
Circulating cytokine concentrations
RESULTS
Clinical results
N o significant differences in pretreatment character istics were observed between both treatment groups except for the number of painful joints which was higher in the group treated with combination therapy (Table I) . After 24 weeks o f treatment, improvement was observed in both treatment groups. However, the combination therapy proved to be superior to M TX alone as reflected by the more pronounced changes in clinical variables including the Ritchie Articular Index, D A S, number o f swollen and painful joints, general well-being, pain score, grip strength (Table I) 
Baseline comparisons in cytokine concentrations
Compared to healthy controls, the circulating con centrations of IL-6, soluble T N F and IL-2 receptors and IL-1RA and the spontaneous production of secreted and cell-associated IL-1 /?, TNFa and IL-1RA by PBM NC were significantly higher in RA patients (Table II) . The production of cell-associated cytokines after in vitro stimulation was also higher in RA patients and this difference was significant for TN Fa and IL-1RA. In contrast, the concentrations of IL-1/? and TN Fa in the circulation and the secreted amount of IL-1/?, TN Fa and IL-1RA after PBMNC stimulation were similar in patients and controls (Table II) PB M N C RA ( Fig. 2A and B) after sd to be higher (not significant) in patients treated with M TX + SASP, and significant decreases during follow-up were only observed in this treatment group. The secreted amount of IL-1/? after PBM NC stimu lation decreased after 4 weeks, especially in the group treated with M TX alone, however, the median values at week 24 were not significantly different from baseline (Fig. 2C) . Neither the circulating levels of IL-1RA (Fig. IE), IL-1/?, and T N F a nor 
Interrelationships between cytokines and other p a r a m eters
sTNFR and sIL-2R showed positive correlations with the DAS, number of swollen joints, C-reactive protein (CRP) and IL-6 and negative correlations with haemoglobin concentrations (Table III) Several o f the parameters studied showed important changes during therapy and there were some differ ences between both therapy groups. Significant decreases in the circulating sT N FR levels and in the production of cell-associated IL-l/i and IL-1RA after stimulation were only observed in patients treated with M TX -I-SASP but not in the M TX group (Figs 1 and  2) . This difference may reflect the fact that baseline levels of these parameters were higher (not significant) in the group treated with MTX -I-SASP, and that decreases are more likely to occur in this case. On the hand, it might result from an additional or specific effect o f SASP on the release of T N F receptors and on the production ofIL-1 and its antagonist. Early decreases in IL-6 and sIL-2R concentrations occurred in both therapy groups, being also more marked in the group with higher pretreatment levels whereas the levels of IL-l/i, T N Fa and IL-1RA in the circulation remained unchanged.
We have previously demonstrated that MTX therapy does not alter T N Fa but reduces IL-6 and sIL-2R concentrations [19] and this has been corroborated by other authors [20, 41] . However, our findings in patients receiving combination therapy do not support the claim that SASP reduces circulating levels o f IL-l/i and T N Fa as reported by Danis et al. [32] .
In patients with active RA, we have observed reductions in the secretion o f IL-l/i by stimulated (Table II) . Elevated concentrations o f IL-6 [42, 43] , sIL-2R [18] [19] [20] and sT N FR [19, 21] have been previously re ported in RA. These parameters are interrelated and show positive correlations with some measures of disease activity (Table III) . Therefore, a decrease in their circulating levels during therapy probably reflects clinical improvement. Although it is not likely that these parameters will supersede current disease activity assessments, they may have some value as activity markers. In contrast, the concentrations of IL-l/i [44, 45] •ession in rheumatoid
